Amgen discloses data breach involving patient health information
A view of the Amgen logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. REUTERS/Mike Blake
Read a summary of this article on FAST.
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
July 31 : Drugmaker Amgen said on Friday hackers stole company data and patient health information in a cybersecurity incident involving cloud storage systems run by third-party providers, becoming the latest healthcare firm to disclose a breach.
On July 29, Amgen determined the incident was material, based on its evaluation of how many files appeared to be affected and the possibility that the information in those files could be sensitive, it said in a regulatory filing.
The healthcare sector has been grappling with a surge in cyberattacks, with Abbott Laboratories, Clover Health, Stryker, Medtronic, Novo Nordisk and West Pharmaceutical Services among the companies recently affected.
Amgen has activated its cybersecurity response plan, put containment measures in place, and brought in independent forensic experts to investigate.
Guess Word
Crack the word, one row at a time
Buzzword
Create words using the given letters
Mini Sudoku
Tiny puzzle, mighty brain teaser
Mini Crossword
Small grid, big challenge
Word Search
Spot as many words as you can
The company said it was assessing whether and/or the extent to which patient, confidential business information, intellectual property, research and development, or other information may have been accessed or stolen.
To date, it said it has not found any impact on its products, manufacturing operations, financial reporting systems, or its ability to meet patient needs.
The incident comes as Amgen faces scrutiny over its rare-disease drug Tavneos, after a major medical journal retracted a key study backing the treatment and regulators in the United States and Europe sought to remove it from the market.
Amgen said it takes the obligation to protect patient privacy and data security very seriously and that it was still evaluating what regulatory and legal notifications were required and would notify affected parties, including patients, based on its findings.
Source: Reuters
Sign up for our newsletters
Get the CNA app
Stay updated with notifications for breaking news and our best stories
Get WhatsApp alerts
Join our channel for the top reads for the day on your preferred chat app
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
About The Author
